Waylivra FDA Approval Status
FDA Approved: No
Brand name: Waylivra
Generic name: volanesorsen
Company: Akcea Therapeutics, Inc.
Treatment for: Familial Chylomicronemia Syndrome
Waylivra (volanesorsen) is an antisense oligonucleotide apolipoprotein C-III (ApoC-III) inhibitor in development for the treatment of familial chylomicronemia syndrome (FCS).
Development timeline for Waylivra
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.